+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis



Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis



Dermatitis 26(3): 122-132



Topical calcineurin inhibitors (TCIs) are widely used as an alternative to topical corticosteroids (TCSs) in treating of atopic dermatitis, but their risk versus benefit compared with TCSs remains unclear. We performed a systematic review of the efficacy, safety, and cost-effectiveness of TCI compared with TCS and emollients. Published meta-analysis, systematic reviews, and individual studies from January 2005 to January 2015 on the comparative efficacy, safety, and cost-effectiveness of TCI against emollients and TCS were included. Tacrolimus is comparable to TCS in efficacy, safety profile, and cost-effectiveness. Pimecrolimus has a similar safety profile compared with TCS, emollients, and tacrolimus. It is superior to emollients but inferior to TCS and tacrolimus in efficacy and cost-effectiveness. The association of tacrolimus with malignancy remains uncertain. Tacrolimus is an efficacious and cost-effective alternative to TCS, but its benefits need to be weighed against its still uncertain risk for malignancy. Pimecrolimus is appropriate for mild atopic dermatitis when TCS or tacrolimus is unsuitable.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058962442

Download citation: RISBibTeXText

PMID: 25984688

DOI: 10.1097/DER.0000000000000118


Related references

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. Bmc Pediatrics 16: 75, 2017

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 6(2): 65-77, 2005

Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. Journal of Dermatological Science 54(2): 76-87, 2009

Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. Journal of the American Academy of Dermatology 75(2): 410-419.E3, 2017

Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. American Journal of Clinical Dermatology 10(2): 103-118, 2009

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211(2): 174-187, 2005

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medgenmed 8(4): 8, 2007

Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Current Allergy and Asthma Reports 6(4): 270-274, 2006

Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. American Journal of Clinical Dermatology 7(4): 213-222, 2006

Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. American Journal of Clinical Dermatology 13(2): 113-123, 2012

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. Journal der Deutschen Dermatologischen Gesellschaft 10(3): 167-172, 2013

Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology 164(2): 415-428, 2011

Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatric Drugs 15(4): 303-310, 2013

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, and Clinical Immunology 9(1): 24-24, 2013